NPC in Specialty Pharmacy Times: How Can We Advance Progress in Moving from Volume to Value in Health Care?
(2/7, National Pharmaceutical Council: E.V.I.dently Today) comments “...In his latest column in Specialty Pharmacy Times, National Pharmaceutical Council President and Chief Executive Officer Dan Leonard explains that rather than trying to score news headlines, what we need is a thoughtful, research-based approach to tackle the challenges ahead of us. Looking through the lens of NPC's research and collaborative activities, Mr. Leonard outlines how we can address the issues raised in the administration's blueprint and move toward a more value-based health care system.” Full
How Can We Advance Progress in Moving From Volume to Value in Health Care?
(1/22, Dan Leonard, Specialty Pharmacy Times) comments “...As we highlighted in our comments to HHS, value-based insurance design could change medicine for the better if grounded in a strong evidence base. It shifts the focus from how much we spend on health care to how well we spend it. We also see promise in variable cost sharing in pharmacy benefits, especially if patients encounter higher medication costs due to biological reasons rather than personal preference. Variable cost sharing can reduce out-of-pocket expenditures and thus help remove cost barriers and increase medication adherence.” Full
New Cures Coming From Value-Based Outcome Medicine
(2/7, Matthew Kandrach, Morning Consult) comments “...One way is for industry to embrace more innovative payment models that ensure patients only pay for a product if it works for them. Biopharmaceutical manufacturers and health insurers are increasing their focus on value-based outcome programs, whereby the cost of the medicine is reimbursed if it is not effective for a patient after a certain period. In July 2018, Novartis announced it would offer a value-based outcome contract for its acute leukemia medication Kymriah. AstraZeneca, in partnership with Express Scripts, offers a program to reimburse the cost of the lung cancer drug Iressa, as well.” Full
Precision Medicine's Rosy Predictions Haven't Come True. We Need Fewer Promises and More Debate
(2/7, Michael J. Joyner and Nigel Paneth, STAT News) comments “...We are calling for an open debate, in all centers of biomedical research, about the best way forward, and about whether precision medicine is really the most promising avenue for progress. It is time for precision medicine supporters to engage in debate — to go beyond asserting the truism that all individuals are unique, and that the increase in the volume of health data and measurements combined with the decline in the cost of studying the genome constitute sufficient argument for the adoption of the precision medicine program.” Full
England And Canada Collaborate On Parallel Scientific Advice For HTA
(2/7, Francesca Bruce, Pink Sheet) reports “...NICE said that collaboration between HTA bodies across the world would lead to better evidence generation and patient access to new and cost-effective technologies. CADTH added that it is ‘extremely grateful for the collaborative spirit of HTA agencies,’ particularly during the development of its scientific advice program when it drew on the experience of NICE and other agencies.” Paid Subscription Required
Report Identifies Areas Lacking Good Practice in Health Tech Assessment
(2/7, HealthDay News) reports “...‘We identified three areas where few good practices in HTA have been developed or where there is no clear consensus,’ a coauthor said in a statement. ‘In my opinion, the area of integrating social values is the most important and underdeveloped aspect of HTA. HTA bodies have increasingly been exploring how to best integrate social values, particularly patient values, but many fall short of standards for deliberative processes that are fair and transparent.’” Full
Rx.Health and Roche Partner to Support Digital Transformation and Real World Evidence
(2/7, Rx.Health Press Release) “...Rx.Health announced that it has entered into a five-year collaboration focused on personalized healthcare and the utilization of real world evidence to improve health outcomes in people with Inflammatory Bowel Diseases. The goal of the collaboration is to develop targeted and novel digital care solutions for key gap areas across the disease spectrum, starting by bringing structured data on patient reported outcomes into clinical workflows.” Full
Erenumab in Migraine: Indication of Considerable Added Benefit for Certain Patients
(2/7, IQWiG Press Release) “Erenumab was the first drug of a new drug class for the prophylaxis of migraine to enter the German market in November 2018. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care has now examined whether erenumab has an added benefit. As the data presented by the drug manufacturer showed, erenumab can reduce the burden from migraine in those patients for whom other substances used for prophylaxis have failed or have not been an option.” Full
Real-World Evidence in Rheumatic Diseases: Relevance and Lessons Learnt
Misra DP, Agarwal V.
February 6, 2019, Rheumatology International
Advisory Panel on Clinical Trials Spring 2019 Meeting
May 15, 2019
9:00AM - 2:00PM EDT